Health Care · Services-Commercial Physical & Biological Research

OABI OmniAb, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 184625362 filings
Russell 2000

OABI at a glance

OmniAb, Inc. (OABI, SEC CIK 1846253) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), OmniAb, Inc. (OABI) reported revenue of $18.7 million (down 29.3% from FY2024) and a net loss of $64.8 million. Diluted EPS was -$0.57.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding OmniAb, Inc. (OABI) shares worth $134.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$18.7M
−29.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$134.4M · +0 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $3.993M vs $2.239M, up $1.754M YoY
  • Service revenue $2.835M vs $1.188M, strongest growth from antibody and ion channel programs
  • Q3 net loss $15.728M vs $16.525M, effective tax rate 0.8% vs 6.6%
  • Cash, equivalents and short-term investments $64.2M, sufficient through at least next 12 months
  • Nine-month operating cash flow $8.340M vs $(30.781)M, headwinds from lower platform demand and potential tariffs or trade policies

Risk Factors

  • No material changes to 2025 Annual Report risk factors
  • Carried-forward risk: unknown or currently immaterial factors could materially harm operating results
  • Carried-forward risk: general economic conditions could adversely affect cash flows
  • Carried-forward risk: existing risks could materially weaken financial condition

AI summary of the OABI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • OmniAb reported financial results for Q3 and nine months ended September 30, 2026
  • Exhibit 99.1 contains the substantive earnings release and financial details

Item EX-99.1: Item EX-99.1

  • Q3 revenue rose to $4.0M from $2.2M, while net loss narrowed to $15.7M from $16.5M
  • Nine-month revenue reached $31.8M versus $10.3M, driven primarily by $21.6M in license and milestone revenue
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 and six-month financial results for periods ended June 30, 2026, announced August 6, 2026
  • Detailed results and management commentary contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $13.4M vs $3.9M, driven primarily by milestone revenue; first-half revenue reached $27.8M
  • Net loss narrowed to $5.9M, or $0.05 per share, from $15.9M, or $0.15, year over year
Filed Jul 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Amechi Nwachuku appointed COO effective July 13, 2026, adding senior commercial leadership across life sciences and diagnostics
  • Initial base salary $445,000, with 45% target annual bonus and $20,000 signing bonus

AI summaries of OABI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OABI

Don't miss the next OABI filing

  • Alerts as it files. A push when OABI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OABI, by share count.
  • Ask anything. An AI agent that reads every OABI filing and answers with sources.

OABI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Love StevenMNov 1, 2026-
Love StevenMNov 1, 2026-
Nwachuku Amechi EkekeAAug 1, 2026-
Crouse Steven C.AJun 17, 2026-
Cochran Jennifer R.MJun 17, 2026-
Crouse Steven C.AJun 17, 2026-
Gotwals Philip JMJun 17, 2026-
Crouse Steven C.MJun 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$26.4M$18.7M
Operating Income--$74.5M-$69.0M
Net Income-$50.6M-$62.0M-$64.8M
Op. Margin--282.3%-369.5%
Net Margin--235.1%-347.0%
Balance Sheet
Total Assets-$325.6M$300.9M
Equity$314.6M$287.6M$267.0M
ROE-16.1%-21.6%-24.3%
Per Share
EPS$-0.51$-0.61$-0.57
Cash Flow
Operating CF--$39.7M-$36.5M
CapEx$1.6M$1.9M$565K

Source: XBRL data in OmniAb, Inc. (OABI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OABI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OABI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$134.4M
Q2 202624$55.2M
Q1 202624$33.6M
Q4 202522$42.2M
Q3 202524$37.7M
Q2 202525$42.8M
Q1 202519$33.3M
Q4 202415$43.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OABI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 2, 2026--
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Aug 3, 2026--
8-KJul 13, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
8-KJun 18, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
4Apr 21, 2026--
4Apr 21, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
10-KMar 4, 2026-
8-KMar 4, 2026Analysis-
4Feb 18, 2026-
4Feb 17, 2026-

Related Health Care companies

All Health Care →

OABI SEC filings: frequently asked questions

Which institutions hold OABI stock?

As of September 30, 2026, the largest OmniAb, Inc. (OABI) holders among the 13F filers tracked by SignalX were BlackRock ($48.3 million), Vanguard Capital Management LLC ($18.7 million), State Street Corp ($11.3 million), Prudential Financial ($7.0 million), Two Sigma Investments ($6.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OABI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), OmniAb, Inc. (OABI) reported revenue of $18.7 million (down 29.3% from FY2024) and a net loss of $64.8 million. Diluted EPS was -$0.57. The figures come from the XBRL data in the 10-K.

What did OABI report in its latest 8-K?

OmniAb, Inc. (OABI) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). OmniAb reported financial results for Q3 and nine months ended September 30, 2026.

What are the latest OABI SEC filings?

OmniAb, Inc. (OABI) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 2, 2026.

What is OABI's SEC CIK number?

OmniAb, Inc. (OABI)'s SEC Central Index Key (CIK) is 1846253. EDGAR lists every OABI filing under that number.

Ask anything about OABI

The research agent reads OABI's filings, financials, insider trades and 13F holders, then answers with sources.